Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00550537 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: bevacizumab
DRUG: carboplatin
DRUG: erlotinib hydrochloride
DRUG: paclitaxel
GENETIC: gene expression analysis
GENETIC: protein expression analysis
GENETIC: proteomic profiling
OTHER: laboratory biomarker analysis

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]